Navigation Links
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Date:3/20/2008

- First New Agent for CLL Patients Approved by the FDA since 2001 -

FRAZER, Pa., March 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. The American Cancer Society estimates that more than 15,000 new cases of this rare disease will be diagnosed in the United States this year. The TREANDA application as a CLL treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon anticipates that TREANDA will be available to physicians and patients as a CLL treatment in the United States in April 2008.

To view the Multimedia News Release, go to:

http://www.prnewswire.com/mnr/treanda/32349/.

"TREANDA is an important new treatment for patients with chronic lymphocytic leukemia, and this first-cycle approval by FDA represents a significant milestone in the growth of our oncology business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "With a strong pipeline of near- and longer-term opportunities, Cephalon Oncology is poised to deliver therapies that target both hematologic cancers and solid tumors for patients in need of new options."

Dr. Bruce Cheson, Clinical Professor of Hematology/Oncology, Georgetown University School of Medicine, Washington D.C., stated, "Patients with chronic lymphocytic leukemia can often live normal lives for many years because of treatments that control the disease over the long-term. TREANDA is an effective new option that offers a delay in disease progression, an important goal for patients with chronic lymphocytic leukemia."

In a randomized, international, m
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
2. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
3. Cephalon General Counsel John E. Osborn to Resign Position
4. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
5. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
6. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
8. Cephalon Submits Supplemental New Drug Application for FENTORA
9. Cephalon Announces Strong Third Quarter Financial Results
10. Cephalon Quarterly Conference Call Invitation
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for ... advancing knowledge and research in reproductive medicine. In ... a seat on the executive board and will have ... , Dr. Hill has actively supported ASRM since 1984 ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... LifeQuest World Corporation,(OTC Bulletin Board: LQWC) is ... work, ImmunXT, their Immune System enhancement supplement, has,been ... as of March 2008.,ImmunXT has been proclaimed as ... ImmunXT (US Patent #7,205,284 B2),is a bio-active Micro-algae ...
... (OTC Bulletin Board: GNTA) announced today that it ... (FINRA, formerly,the NASD) has cleared a market maker,s ... the Over-the-Counter Bulletin Board (OTCBB). As a,result, the ... Company,s,common stock will begin on Wednesday, May 7, ...
... Calif., May 6 Kosan Biosciences,Incorporated (Nasdaq: ... Vice,President, Corporate Communications, will present at the Leerink ... the Grand Hyatt Hotel on,Friday, May 9, 2008 ... the presentation,can be accessed through http://www.wsw.com/webcast/leerink15/kosn/ ., ...
Cached Biology Technology:LifeQuest World Launches Immune System Boosting Supplement to the North American Market 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 3Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference 2
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... gene therapy reversed course of disease in mouse modelsIn ... disease, scientists were able to reverse the rodents' memory ... is crucial for the development of Alzheimer's disease. , ... that stopping the synthesis of a protein that is ...
... Billions of people tuned into recent Live 8 concert ... the altruistic cause spearheaded by former Boomtown Rat, Sir ... of us look out for each other, while others ... natural selection has designed individuals to behave selfishishly; selfish ...
... medically important fungus, causing potentially life-threatening infections in patients ... cause of respiratory allergy, and it is implicated in ... to lack the ability to reproduce sexually, but new ... the fungus has a number of characteristics of sex. ...
Cached Biology News:Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 2Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 3Helping in a selfish world 2Secret sex life of killer fungus? 2
Recombinant Rat Leptin, CF...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
... 25 mL pipets ,Angled acrylic pipet rack offers ... or round pipet cans. Constructed of 6 mm (1/4 ... W x 76 mm H x 289 mm D ... 89 mm W x 406 mm H x 292 ...
... Contact Printing Kit contains choice of PDMS ... of 100 / 200 micron squares or ... um x 10 mm lines, 3 PDMS ... or 60 nm and pitch of 400 ...
Biology Products: